RhumbLine Advisers
TNGX icon

RhumbLine Advisers’s Tango Therapeutics TNGX Stock Holding History

RhumbLine Advisers’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.65M Sell
126,603
-2,504
-2% -$34.9K ﹤0.01% 1717
2025
Q4 		$1.14M Buy
129,107
+21,268
+20% +$183K ﹤0.01% 2155
2025
Q3 		$906K Sell
107,839
-4,434
-4% -$30K ﹤0.01% 2306
2025
Q2 		$575K Buy
112,273
+45,467
+68% +$112K ﹤0.01% 2598
2025
Q1 		$91.5K Buy
66,806
+1,066
+2% +$2.62K ﹤0.01% 3416
2024
Q4 		$203K Buy
65,740
+1,895
+3% +$8.8K ﹤0.01% 3193
2024
Q3 		$492K Sell
63,845
-3,495
-5% -$33.4K ﹤0.01% 2705
2024
Q2 		$578K Sell
67,340
-4,097
-6% -$31.7K ﹤0.01% 2566
2024
Q1 		$567K Buy
71,437
+1,047
+1% +$11.2K ﹤0.01% 2588
2023
Q4 		$697K Buy
70,390
+624
+0.9% +$5.42K ﹤0.01% 2480
2023
Q3 		$786K Sell
69,766
-859
-1% -$5.24K ﹤0.01% 2345
2023
Q2 		$234K Sell
70,625
-1,096
-2% -$3.94K ﹤0.01% 3156
2023
Q1 		$283K Buy
71,721
+1,031
+1% +$5.98K ﹤0.01% 2633
2022
Q4 		$513K Buy
70,690
+938
+1% +$6.6K ﹤0.01% 2450
2022
Q3 		$253K Buy
69,752
+3,818
+6% +$16.3K ﹤0.01% 2807
2022
Q2 		$299K Buy
+65,934
New +$399K ﹤0.01% 2753

Other funds holding TNGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

RhumbLine Advisers's TNGX Position: Q1 2026 in Review

RhumbLine Advisers reduced its Tango Therapeutics (TNGX) stake by 1.9% in Q1 2026, selling an estimated $34.9K and leaving 126,603 shares worth $2.65M. The position accounts for ﹤0.01% of the portfolio, ranked #1717.

RhumbLine Advisers first reported a position in TNGX in Q2 2022 and has held it in 16 quarters since. 194 funds tracked by Wall St. Rank hold TNGX as of Q1 2026.

  • RhumbLine Advisers held 126,603 shares of Tango Therapeutics worth $2.65M as of Q1 2026.
  • RhumbLine Advisers sold 2,504 Tango Therapeutics shares in Q1 2026, an estimated $34.9K.
  • Tango Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #1717 holding.
  • RhumbLine Advisers first reported a position in Tango Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • 194 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.